Chongqing Precision Biotech Co., Ltd. announced that its CAR-T therapy, Puzolcabtagene Autoleucel Injection (PCAR-19B), has been included in the “Personal Clinic Policy of Zhongan”commercial health insurance program, with coverage of up to RMB 998,000.

Since its approval by the NMPA on November 7, 2025, the therapy has been incorporated into multiple regional and supplemental insurance programs across China, including West Lake Benefit United Insurance 2026 Upgraded Version, customized commercial medical insurances of Xinjiang Corps, Heilongjiang, Hebei and Jiangxi.